Search Videos by Topic or Participant
Browse by Series:

Managing Skeletal-Related Events in Breast Cancer, Part I

Panelists: William J. Gradishar, MD, Northwestern;Joyce O’Shaughnessy, MD, Texas Oncology; Christy A. Russell, MD, USC Norris; Debu Tripathy, MD,
Published Online: Monday, Dec 03, 2012
For High-Definition, Click
Skeletal-related events (SREs) are common when administering both hormonal therapy and chemotherapy for patients with breast cancer. In recent years, several new treatment options have been approved that significantly help reduce SREs and improve quality of life.

Joyce A. O’Shaughnessy, MD, discusses results from clinical trials that compared the RANK ligand inhibitor denosumab to zoledronic acid in several tumor types. Overall, in metastatic breast cancer, denosumab showed superiority at reducing the occurrence of SREs. O'Shaughnessy explains that both these treatments are reasonable options but that she prefers denosumab for patients with newly diagnosed bone metastases or those progressing on IV bisphosphonates.

Christy A. Russell, MD, notes that a shortcoming of these trials is a lack of long-term data. Additionally, she feels the dosing schedule can be improved upon further. Moderator, Debu Tripathy, MD, believes that translating these agents into the early stage setting is one of the biggest challenges facing researchers.

View >>> Managing Skeletal-Related Events in Breast Cancer, Part II


Slider Left
Slider Right
For High-Definition, Click
Skeletal-related events (SREs) are common when administering both hormonal therapy and chemotherapy for patients with breast cancer. In recent years, several new treatment options have been approved that significantly help reduce SREs and improve quality of life.

Joyce A. O’Shaughnessy, MD, discusses results from clinical trials that compared the RANK ligand inhibitor denosumab to zoledronic acid in several tumor types. Overall, in metastatic breast cancer, denosumab showed superiority at reducing the occurrence of SREs. O'Shaughnessy explains that both these treatments are reasonable options but that she prefers denosumab for patients with newly diagnosed bone metastases or those progressing on IV bisphosphonates.

Christy A. Russell, MD, notes that a shortcoming of these trials is a lack of long-term data. Additionally, she feels the dosing schedule can be improved upon further. Moderator, Debu Tripathy, MD, believes that translating these agents into the early stage setting is one of the biggest challenges facing researchers.

View >>> Managing Skeletal-Related Events in Breast Cancer, Part II
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
13th Annual School of Breast Oncology® OnlineJan 29, 201724.25
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 19, 20173.0
Publication Bottom Border
Border Publication